CJC-1295 with DAC

Laboratory Peptide: CJC-1295 with DAC Technical Documentation

CJC-1295 with DAC (Drug Affinity Complex) represents a bioengineered peptide compound synthesized as an enhancement to the endogenous secretory agent growth hormone–releasing hormone (GHRH). The formulation addresses inherent biochemical limitations through rational molecular design intended to strengthen resistance to breakdown and prolong the active period. Incorporation of the DAC component enables binding to serum albumin, thereby safeguarding the molecule from glomerular filtration and proteolytic attack. The culmination is a substantially protracted period of growth hormone secretion stimulation significantly surpassing that achieved through administration of native GHRH compounds.

Biochemical Mechanism and Regulatory Physiology

CJC-1295 modified with a Drug Affinity Complex functions as an extended-release peptide agonist of GHRH formulated to deliver enhanced stability and amplified duration of GH secretion stimulation. The mechanism depends upon binding of the peptide to GHRH receptors residing on anterior pituitary somatotroph cells, activating complex intracellular signaling networks that engender the physiologically characteristic pattern of pulsatile GH secretion, replicating natural hormonal oscillation.

Following synthesis and exocytosis into the blood compartment, GH directs peripheral and hepatic tissues to produce and export insulin-like growth factor-1 (IGF-1), the paramount molecular mediator of anabolic metabolism, regenerative processes, and proliferative cellular activity. The cooperative regulatory action of GH alongside IGF-1 constitutes a critical control apparatus governing energy substrate utilization, triglyceride mobilization from adipose tissues, and nitrogen retention in muscular compartments. Significantly, GH facilitates the hydrolysis of stored lipids across multiple fat depot locations while simultaneously supporting the structural integrity of muscle tissue.

A distinguishing benefit of the DAC modification concerns the enhanced capacity of the peptide to form stable albumin-peptide complexes within circulating blood. This interaction produces a dramatic extension of the peptide's half-life, sustaining persistent receptor signaling and uninterrupted GH output. Therefore, CJC-1295 with DAC sustains biological functionality spanning multiple days extending into weeks—substantially outperforming non-DAC alternatives including unmodified CJC-1295 or native GHRH(1-29).

At the cellular biochemical level, CJC-1295 occupation of GHRH receptor binding sites is theorized to activate adenylate cyclase-catalyzed cAMP synthesis. This triggers activation of protein kinase A (PKA), which catalyzes phosphorylation of nuclear transcription-regulating proteins, enhancing expression of genes encoding GH within pituitary cells. The prolonged circulation of the albumin-bound variant perpetuates these signaling events, generating amplified cumulative GH release and heightened IGF-1 serum levels in comparison to rapidly-cleared peptide compounds.

In summary, CJC-1295 with DAC operates as an invaluable research model for illuminating sustained endocrine activation pathways, mapping the GH/IGF-1 control system architecture, and determining metabolic and physiological consequences stemming from protracted GH pulsatility.

Molecular Composition and Chemical Specifications

Biochemical Characterization

Appearance: White freeze-dried powder

Molecular Formula: C₁₆₅H₂₇₁N₄₇O₄₆

Molecular Weight: Approximately 3647.9 Daltons

Sequence Composition: GHRH(1–29) variant bearing covalent DAC attachment

Purity Specification: ≥ 98% per analytical certification

CJC-1295 with DAC: Experimental Methodologies and Quality Control

Temperature Control and Preservation Requirements

CJC-1295 with DAC arrives as a purified, lyophilized powder formulation prepared for scientific research applications. To ensure complete retention of three-dimensional molecular architecture and bioactive properties, storage in the anhydrous state at –20°C is required. After solubilization in appropriate aqueous vehicles, the solution must be processed using aseptic sterile methods and held at 2–8°C for use during short-term experimental windows. These storage requirements ensure preservation of molecular configuration and substantially eliminate the possibility of chemical degradation or microbial colonization during investigative work.

Stimulation of GH Secretion and Kinetics

Clinical studies in human subjects and preclinical investigations in animal models demonstrate that administration of a single dose of CJC-1295 with DAC produces increased GH and IGF-1 concentrations persisting for roughly one week. This protracted elevation in circulating hormones provides stark contrast to the transient response observed with unaltered GHRH(1-29) or earlier non-DAC peptide variations. Quantitative measurements show IGF-1 approximately 2–3 times baseline with coordinated pulsatile GH secretion, confirming potent receptor activation and extended peptide persistence in blood.

Metabolic and Physiological Modifications

Research indicates CJC-1295 with DAC engenders substantial metabolic changes by raising available GH and IGF-1. Preclinical study results document increased lipid breakdown rates, accelerated fat oxidative utilization, and sustained muscle mass, all consistent with known GH physiological roles. Assessment has encompassed the peptide's impact on protein assembly mechanisms, tissue healing acceleration, and overall energy expenditure modification, establishing utility as a research probe for investigating GH-dependent metabolic pathways.

Pharmacokinetic Profile and Bioavailability Duration

Contrasting with fast-acting GHRH variants, the DAC structural element allows CJC-1295 to establish strong albumin binding, substantially decreasing both kidney filtration and enzymatic destruction. This robust interaction between the peptide and circulating albumin dramatically extends the time period during which the compound maintains biochemical activity, enabling sustained receptor stimulation and prolonged endocrine output. Pharmacokinetic modeling indicates an elimination half-life of approximately 5.8 to 8.1 days, substantially lengthier than the minutes-to-hours clearance seen with non-albumin-conjugated peptides, thereby reducing dosing frequency in experimental protocols.

Academic Authorship and Professional Attribution

Document Assembly and Scholarly Organization

This comprehensive scientific literature compilation was meticulously assembled, thoroughly reviewed, and logically organized by Dr. Stuart L. Teichman, M.D. An internationally respected endocrinologist and clinical research specialist, Dr. Teichman has spearheaded pioneering investigations into extended-duration GHRH-based compounds, particularly CJC-1295. His definitive studies have delineated the pharmacological profile, safety considerations, and therapeutic promise of GHRH-derived peptides, demonstrating potent capacity to sustain elevated GH and IGF-1. Dr. Teichman's intellectual work has substantially shaped contemporary knowledge in peptide endocrinology and rational design of long-acting hormonal medications.

Peer-Reviewed Publications and Scientific Partnerships

Throughout his research trajectory, Dr. Stuart L. Teichman has concentrated on the scientific investigation of GH-releasing peptides, GHRH compound variants, and endocrine modulation mechanisms via peptide technology. Working alongside accomplished colleagues A. Neale, B. Lawrence, and C. Gagnon, Dr. Teichman has produced extensive peer-reviewed scientific literature illuminating the operational mechanisms of extended-duration GHRH analogs, their regulatory modulation of the GH/IGF-1 network, and their systemic physiological-metabolic effects. His accumulated scientific achievement provides a critical knowledge basis for creation of advanced peptide-based therapeutic preparations directed toward endocrine equilibrium and metabolic optimization.

This attribution serves exclusively as recognition of scientific contribution and does not represent institutional backing, marketing language, or professional alignment. Montreal Peptides Canada maintains no commercial partnership, funding association, or professional collegium with Dr. Teichman or any cited collaborators.

Literature References and Academic Sources

Teichman SL, Neale A, Lawrence B, Gagnon C, et al. Prolonged stimulation of GH and IGF-1 secretion by CJC-1295, a long-acting GHRH analog. J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/

Broglio F, et al. Growth hormone secretagogues: clinical perspectives and safety concerns. Growth Horm IGF Res. 2009;19(1):1-9. https://pubmed.ncbi.nlm.nih.gov/19054601/

Ghigo E, et al. Growth hormone secretagogues: physiology and clinical applications. Endocr Rev. 2005;26(3):345-376. https://pubmed.ncbi.nlm.nih.gov/15814849/

Anderson-Baucum EK, et al. GH/IGF-1 axis and metabolic regulation. Mol Cell Endocrinol. 2018;469:1-14. https://pubmed.ncbi.nlm.nih.gov/29288913/

Wu Z, et al. Growth hormone and IGF-1 signaling in muscle metabolism. Front Endocrinol (Lausanne). 2020;11:607. https://pubmed.ncbi.nlm.nih.gov/33281526/

Ranke MB, Wit JM. Growth hormone-past, present and future. Nat Rev Endocrinol. 2018;14(5):285-300. https://pubmed.ncbi.nlm.nih.gov/29479014/

Strasburger CJ, et al. GH and IGF-1 in clinical practice: new insights. Eur J Endocrinol. 2021;185(6):R123-R136. https://pubmed.ncbi.nlm.nih.gov/34870144/

Smith TR, et al. The role of GH and IGF-1 in tissue repair and regeneration. Exp Gerontol. 2015;68:46-52. https://pubmed.ncbi.nlm.nih.gov/25987250/